REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
08/17/2026
Back to search
Official data from USPTO
REPERTOIRE IMMUNE MEDICINES
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
REPERTOIRE IMMUNE MEDICINES
ST13
US500000088774070Class
5
Filing
88774070
Registration
6457885
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
43
Latest update
08/17/2026
Trademark type
Word
Nice classes
5
Filing date
01/27/2020
Registration date
08/17/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/17/2021
Last transaction
08/17/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Supplemental Register
Filing basis
Intent to use
First use anywhere
2020-12-00
First use in commerce
2020-12-00
Drawing code
4
Owner type
03
Owner location
CAMBRIDGE, MA, US
Examiner
YOUNG, THOMAS PAUL
Law office
N20
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
REPERTOIRE IMMUNE MEDICINES, INC.
Cogen Immune Medicine, Inc.
Representatives
CHRISTINA M. LICURSI WOLF, GREENFIELD & SACKS, P.C.
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
therapeutic products for medical purposes in the nature of biological preparationsbiological tissue cultures and cell-based therapeutics in the nature of genetically modified cells used to modulate an immune response; pharmaceutical preparations used to modulate an immune response; pharmaceuticals and medical preparations for immunotherapycell therapyimmune cell therapyT-cell therapy for use in the prevention and treatment of cancertumorsdiseases and disorders of the immune system; pharmaceuticals and medical preparations for use in the prevention and treatment of cancertumorsdiseases and disorders of the immune system; pharmaceuticals and medical preparations in the nature of biotherapeuticsimmunotherapeuticsimmunomodulatorsimmunostimulantsimmunogenicsantibodiescell therapeuticscellsimmune cellsT-cells for use in the prevention and treatment of cancertumorsdiseases and disorders of the immune system
Publications
History of USPTO decisions and trademark events.
43 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/07/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/07/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/07/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/07/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/07/2025
EXPT
EXPARTE APPEAL TERMINATED
08/17/2021
R.SR
REGISTERED-SUPPLEMENTAL REGISTER
08/17/2021
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
07/13/2021
CNTA
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
07/12/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/12/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/12/2021
ALIE
ASSIGNED TO LIE
07/12/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/27/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
05/25/2021
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
05/25/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
05/25/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
05/25/2021
AAUA
NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
02/12/2021
GEAN
NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
02/11/2021
GEAP
EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED
02/11/2021
EPEN
COMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY
02/11/2021
CPEA
EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED
02/11/2021
IUAA
USE AMENDMENT ACCEPTED
02/11/2021
AUPC
AMENDMENT TO USE PROCESSING COMPLETE
02/04/2021
IUAF
USE AMENDMENT FILED
02/04/2021
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
02/03/2021
EAAU
TEAS AMENDMENT OF USE RECEIVED
02/03/2021
EXPI
EX PARTE APPEAL-INSTITUTED
02/03/2021
JURT
JURISDICTION RESTORED TO EXAMINING ATTORNEY
02/03/2021
EXAF
EXPARTE APPEAL RECEIVED AT TTAB
02/03/2021
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
08/03/2020
GNFR
FINAL REFUSAL E-MAILED
08/03/2020
CNFR
FINAL REFUSAL WRITTEN
08/03/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/15/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/14/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/14/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/21/2020
GNRT
NON-FINAL ACTION E-MAILED
04/21/2020
CNRT
NON-FINAL ACTION WRITTEN
04/21/2020
DOCK
ASSIGNED TO EXAMINER
04/15/2020
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
04/08/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/30/2020
Continuous trademark protection
Get notified about every new filing that threatens REPERTOIRE IMMUNE MEDICINES or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.